Cure My Disease
Don't miss your cure!
Clinical trials sponsored by Pharmacyclics Switzerland Gmbh, explained in plain language.
This study offers ongoing access to ibrutinib for 297 people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and still benefit from the drug but cannot get it commercially. Participants continue their current treatment while research…
Phase: PHASE4 • Sponsor: Pharmacyclics Switzerland GmbH • Aim: Disease control
Last updated May 20, 2026 11:56 UTC